Axsome Therapeutics Inc has a consensus price target of $110.21, established from looking at the 85 latest analyst ratings. The last 3 analyst ratings were released from Mizuho, Truist Securities, and RBC Capital on March 28, 2024, March 26, 2024, and March 26, 2024. With an average price target of $129 between Mizuho, Truist Securities, and RBC Capital, there's an implied 62.24% upside for Axsome Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/28/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 37.09% | Mizuho | Graig Suvannavejh | $108 → $109 | Maintains | Buy | Get Alert |
03/26/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 88.66% | Truist Securities | Joon Lee | → $150 | Maintains | Buy | Get Alert |
03/26/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 60.99% | RBC Capital | Leonid Timashev | $123 → $128 | Maintains | Outperform | Get Alert |
03/26/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 59.73% | Citigroup | David Hoang | $125 → $127 | Maintains | Buy | Get Alert |
03/26/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 138.96% | HC Wainwright & Co. | Raghuram Selvaraju | $180 → $190 | Maintains | Buy | Get Alert |
03/20/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 126.39% | HC Wainwright & Co. | Raghuram Selvaraju | → $180 | Reiterates | Buy → Buy | Get Alert |
03/19/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 35.83% | Baird | Joel Beatty | → $108 | Initiates | → Outperform | Get Alert |
03/04/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 126.39% | HC Wainwright & Co. | Raghuram Selvaraju | → $180 | Reiterates | Buy → Buy | Get Alert |
02/27/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 35.83% | Mizuho | Graig Suvannavejh | $112 → $108 | Maintains | Buy | Get Alert |
02/21/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 57.21% | Guggenheim | Yatin Suneja | $110 → $125 | Maintains | Buy | Get Alert |
02/21/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 54.7% | RBC Capital | Leonid Timashev | $126 → $123 | Maintains | Outperform | Get Alert |
02/21/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 29.54% | Cantor Fitzgerald | Charles Duncan | $108 → $103 | Maintains | Overweight | Get Alert |
02/20/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 35.83% | Cantor Fitzgerald | Charles Duncan | → $108 | Reiterates | Overweight → Overweight | Get Alert |
02/16/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 40.86% | Mizuho | Graig Suvannavejh | $90 → $112 | Maintains | Buy | Get Alert |
02/06/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 39.61% | UBS | Ashwani Verma | → $111 | Initiates | → Buy | Get Alert |
01/25/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 58.47% | RBC Capital | Leonid Timashev | → $126 | Initiates | → Outperform | Get Alert |
01/22/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 35.83% | Cantor Fitzgerald | Charles Duncan | → $108 | Reiterates | Overweight → Overweight | Get Alert |
01/16/2024 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 42.12% | Piper Sandler | David Amsellem | $90 → $113 | Maintains | Overweight | Get Alert |
12/26/2023 | AXSM | Buy Now | Axsome Therapeutics | $79.51 | 126.39% | HC Wainwright & Co. | Raghuram Selvaraju | → $180 | Reiterates | Buy → Buy | Get Alert |
The latest price target for Axsome Therapeutics (NASDAQ: AXSM) was reported by Mizuho on March 28, 2024. The analyst firm set a price target for $109.00 expecting AXSM to rise to within 12 months (a possible 37.65% upside). 43 analyst firms have reported ratings in the last year.
The latest analyst rating for Axsome Therapeutics (NASDAQ: AXSM) was provided by Mizuho, and Axsome Therapeutics maintained their buy rating.
The last upgrade for Axsome Therapeutics Inc happened on August 8, 2023 when B of A Securities raised their price target to $81. B of A Securities previously had an underperform for Axsome Therapeutics Inc.
The last downgrade for Axsome Therapeutics Inc happened on August 10, 2021 when Morgan Stanley changed their price target from $105 to $34 for Axsome Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a maintained with a price target of $108.00 to $109.00. The current price Axsome Therapeutics (AXSM) is trading at is $79.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.